Results 51 to 60 of about 284,250 (248)

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

Determinants of change in the duration of ice phenomena on the Vistula River in Toruń

open access: yesJournal of Hydrology and Hydromechanics, 2015
Winter season temperatures are becoming warmer. However, the transformation of the ice regime on the Vistula River in Toruń has also been affected by river engineering.
Pawłowski Bogusław
doaj   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

Impact Disruption of Bjurböle Porous Chondritic Projectile

open access: yesThe Planetary Science Journal
The ∼200 m s ^−1 impact of a single 400 kg Bjurböle L/LL ordinary chondrite meteorite onto sea ice resulted in the catastrophic disruption of the projectile.
Tomas Kohout   +12 more
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Atmospheric Loss during Giant Impacts: Mechanisms and Scaling of Near- and Far-field Loss

open access: yesThe Planetary Science Journal
The primary epoch of planetary accretion concludes with giant impacts—highly energetic collisions between protoplanets that can play a key role in shaping a planet’s inventory of volatile elements.
Matthew J. Roche   +5 more
doaj   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

open access: yesMolecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal   +4 more
wiley   +1 more source

Measurability of the Heliocentric Momentum Enhancement from a Kinetic Impact: The Double Asteroid Redirection Test (DART) Mission

open access: yesThe Planetary Science Journal
The NASA Double Asteroid Redirection Test (DART) has demonstrated the capability of successfully conducting kinetic impact-based asteroid deflection missions.
Rahil Makadia   +8 more
doaj   +1 more source

Earth-based observations of impact phenomena [PDF]

open access: yesInternational Astronomical Union Colloquium, 1996
Earth-based observations at near- and mid-infrared wavelengths were obtained for at least 15 of the SL9 impacts, ranging from the spectacular G, K and L events to the barely-detected N and V impacts. Although there were a few exceptions, most of the IR lightcurves fit a common pattern of one or two relatively faint precursor flashes, followed several ...
openaire   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy